Skip to content

flash


Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet

Investor Relations Home

Our specialty pharmaceuticals, branded generics and consumer products play a role in helping millions of people live healthier lives and providing treatment to those affected by debilitating diseases. We remain committed to improving the health and well-being of people everywhere, profitably growing our businesses, and bringing value to our shareholders.
Stock Quote
VRX (common stock)
ExchangeNYSE (US Dollar)
Price$32.48
Change (%) Stock is Up 0.35 (1.09%)
Volume1,862,517
Data as of 11/06/09 4:02 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
Second Quarter 2009 Financial Results Conference Call
Investor Fact Sheet 2009
Download Documentation 2008 Annual Report
Current Webcasts and Presentations
Webcast ImageWebcast
Q3 2009 Valeant Pharmaceuticals International Earnings Conference Call (Replay)
11/02/09 at 7:00 a.m. PT
Webcast ImageWebcast
Valeant Pharmaceuticals International at UBS Global Life Sciences Conference (Replay)
09/23/09 at 1:00 p.m. ET
Contacts
General Investor Relations
ir@valeant.com
Phone: (949) 461-6178
Fax: (949)461-6636

Laurie W. Little
Vice President, Investor Relations
Phone: (949) 461-6002
 Proxy and Stock Certificate Questions
American Stock Transfer and Trust Company
6201 15th Avenue
Brooklyn, NY 11219
www.amstock.com
(800) 937-5449

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.